retatrutide obesity triple hormone receptor agonist Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the Dual and Triple Gut Peptide
Description
Newer medications, like tirzepatide, have a dual action, targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
By combining the two drugs, researchers were hoping to preserve muscle mass during weight loss
Additive cardiovascular risk reduction of GLP1a and SGLT2i in diabetic patients with atherosclerotic disease
It is unclear why directionality would vary between studies, although we note these studies were performed in specific disease contexts, and are in substantially smaller samples
Yes, Semaglutide is the active pharmaceutical ingredient in both Ozempic and Wegovy
She was nearly pain-free after she started her infusions
